Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Nanoparticle-Based Vaccines"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 June 2015) | Viewed by 82791
Special Issue Editor
Special Issue Information
Among the many strategies pursued to enhance the efficacy of subunit vaccines in recent years, the use of synthetic or biologically-derived nanoparticles as a platform for vaccine delivery is an approach which has both demonstrated clinical success and has much potential for further development. Effective virus-like particle and virosome-based vaccines have become successful clinical products, demonstrating proof of concept for these strategies. In preclinical studies, nanoparticle display of antigens has been shown to enhance antigen delivery to lymphoid tissues, promote effective priming of humoral immunity, and to promote cellular immune responses in both small and large animal models. Further, the capacity of nanoparticles to co-deliver molecular adjuvants that optimize the immune response, to regulate the kinetics of antigen exposure, and to direct vaccine uptake to appropriate antigen presenting cells are all important ongoing areas of research. Understanding the multifaceted mechanisms of action of nanoparticle vaccines remains an important ongoing challenge that will enable these technologies to further impact prophylactic and therapeutic vaccine development. This special issue of Vaccines will cover all of these topics relevant to nanoparticle vaccine design.
Prof. Dr. Darrell J. Irvine
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- synthetic nanoparticles
- vaccine delivery
- virus-like particles
- vaccine adjuvants